


7TH TROPÉ-KOLSTAD MEETING



2016

Updates and Controversies in Gynecologic Oncology

Friday December 2, 2016
09:00 - 18:00

The auditorium in Building K
Institute for Cancer Research,
The Norwegian Radium Hospital

SPONSORED BY
INGER AND JOHN FREDRIKSEN FOUNDATION FOR OVARIAN CANCER RESEARCH

Welcome to the 7th Tropé-Kolstad meeting on Updates and Controversies in Gynecologic Oncology. This meeting would not have been possible without the generous support of the Inger and John Fredriksen foundation for ovarian cancer research.

During the last year we have seen the long-awaited results from the GOG 252 trial as well as the OV21/PETROC trial in regards to intra-peritoneal chemotherapy in ovarian cancer. The Society of Gynecologic Oncology and the American Society of Clinical Oncology have recently published Clinical Practice Guidelines on Neo-adjuvant chemotherapy for newly diagnosed, advanced ovarian cancer. Are we moving closer to an answer on these topics?

Cancer immunity, homologous recombination deficiency and targeted therapy remain hot topics in Gynecologic Oncology. We are privileged to have a faculty of prominent local and international experts who will present the latest information on these topics, with the hope of advancing and improving our knowledge and the quality of care for patients.

Welcome to this exciting meeting. We hope that you will find the meeting both interesting and informative.

Claes Tropé and Ane Gerda Z Eriksson
Course directors

Tropé-Kolstad Meeting
Updates and Controversies in Gynecologic Oncology

SCIENTIFIC

08:00 - 09:00

REGISTRATION

09:00 - 09:05

WELCOME

Erik Røkkones, MD, PhD, Department of Gynecologic Oncology
The Norwegian Radiumhospital

SESSION 1 Cancer Immunotherapy and Targeted Therapy. State of the art - Chair: Professor Line Bjørge, MD, PhD, MBA

09:05 - 09:35

OUTSOURCING CANCER IMMUNITY TO HEALTHY DONORS

Professor Johanna Olweus, MD, PhD (Norway)

09:35 - 09:40

DISCUSSION

09:40 - 10:10

HOMOLOGOUS RECOMBINATION DEFICIENCY IN OVARIAN CANCER: BEYOND BRCA1 AND BRCA2 MUTATIONS

Professor Douglas Levine, MD (USA)

10:10 - 10:15

DISCUSSION

10:15 - 10:45

IS THERE ANY TARGETED THERAPY OUT THERE?

Professor Christian Marth, MD, PhD (Austria)

10:45 - 10:50

DISCUSSION

10:50 - 11:10

COFFEE BREAK

SESSION 2 Intraperitoneal Chemotherapy - Chair: Stein Larsen, MD, PhD

11:10 - 11:55

INTRA-PERITONEAL CHEMOTHERAPY IN OVARIAN, FALLOPIAN TUBE AND PRIMARY PERITONEAL CANCER, STATE OF THE ART 2016

Professor Carol Aghajanian, MD (USA)

11:55 - 12:00

DISCUSSION

THE 7TH TROPE-KOLSTAD LECTURE - Chair: Professor Emeritus Claes G. Tropé, MD, PhD

12:00 - 12:55

CERVICAL CANCER: PAST, PRESENT, FUTURE

Professor Gunnar B Kristensen, MD, PhD (Norway)

12:55 - 13:50

LUNCH

PROGRAM

SESSION 3 Molecular Characteristics of Gynecological Malignancies - Chair: Anne Dørum, MD, PhD

13:50 - 14:20	TUMORS FROM THE UTERUS WITH SARCOMA IN THEIR NAMES Professor Douglas Levine, MD (USA)
14:20 - 14:25	DISCUSSION
14:25 - 14:55	AN UPDATE IN MOLECULAR PATHOLOGY OF ENDOMETRIAL CARCINOMAS Professor Xavier Matias-Guiu, MD, PhD (Spain)
14:55 - 15:00	DISCUSSION
15:00 - 15:30	MOLECULAR DIFFERENTIATORS OF UTERINE LEIOMYOSARCOMA AND ENDOMETRIAL STROMAL SARCOMA Professor Ben Davidson, MD, PhD (Norway)
15:30 - 15:35	DISCUSSION
15:35 - 15:55	COFFEE BREAK

SESSION 4 Controversies in gynecologic oncology therapy - Chair: Professor Bjørn Hagen, MD, PhD

15:55 - 16:35	PRIMARY DEBULKING SURGERY AND NEO-ADJUVANT CHEMOTHERAPY: ONE SIZE DOES NOT FIT ALL Professor William A. Cliby, MD (USA)
16:35 - 16:40	DISCUSSION
16:40 - 17:00	SECONDARY SURGICAL CYTOREDUCTION IN RECURRENT OVARIAN CANCER: WHO, WHEN AND HOW? Dr. Ane Gerda Z Eriksson, MD (Norway)
17:00 - 17:05	DISCUSSION
17:05 - 17:25	LONG TERM ADVERSE EFFECTS AFTER TREATMENT FOR GERM CELL OVARIAN CANCER: HEARING IMPAIRMENT AND NEUROTOXICITY Dr. Olesya Solheim, MD, PhD (Norway)
17:25 - 17:30	DISCUSSION
17:30 - 17:50	ROBOT-ASSISTED VERSUS OPEN RADICAL HYSTERECTOMY FOR EARLY-STAGE CERVICAL CANCER Dr. M. Bilal Sert, MD (Norway)
17:50 - 17:55	DISCUSSION
17:55 - 18:00	CLOSING REMARKS

Updates and Controversies in Gynecologic Oncology

Johanna Olweus, MD, PhD
Department of Cancer Immunology
Oslo University Hospital
The Norwegian Radium Hospital
Norway



Johanna Olweus is currently Head of Department of Cancer Immunology, Institute for Cancer Research at Oslo University Hospital (OUH) Radiumhospitalet and Professor at the University of Oslo, since 2008. She is also the Director of the K.G. Jebsen Center for Cancer Immunotherapy, which started in June 2013. Olweus did her residency in Immunology and Transfusion Medicine at OUH Rikshospitalet, and received her medical degree and PhD degree at the University of Bergen.

The early research work of Olweus focused on delineating the first steps of hematopoietic lineage commitment. Together with Fridtjof Lund-Johansen she discovered that a progenitor cell population expressing CD123 (IL-3Ralpha) consisted of precursors for plasmacytoid dendritic cells, constituting a new and distinct hematopoietic lineage. The last ten years she has demonstrated that allo-reactive T cell receptors can provide promise in cancer therapy, and has performed in-depth mechanistic studies on successful immunotherapy in lymphoma, correlating T-cell reactivity to autologous tumor to clinical efficacy. More recently, she has also entered the field of neo-antigen research, and together with partner Ton Schumacher in the K.G. Jebsen Center shown that T cells from healthy donors can provide an ample source of neo-antigen reactive T cell receptors. This concept of “outsourcing cancer immunity” is part of the overall strategy of the K.G. Jebsen Center to overcome tolerance to cancer.

Douglas A. Levine, MD, FACOG, FACS
Perlmutter Cancer Center
New York University
USA



Douglas A. Levine is Director of the Gynecologic Oncology Division at the New York University Langone Medical Center in New York City. He received his M.D. from Mount Sinai School of Medicine and completed his residency at Mount Sinai Medical Center and a fellowship at Memorial Sloan Kettering. In addition to his clinical practice, Dr. Levine is the current Head of the Gynecology Research Laboratory, where he studies cancer prevention, precision medicine, and rare tumors with unmet needs. He serves as the translational scientist on many national clinical trials determining what genomic alterations are associated with response to targeted therapies. He discovered universal mutations in SMARCA4 that drive small cell carcinoma of the ovary, hypercalcemic type. Dr. Levine has an outstanding level of expertise and leadership in ovarian and endometrial cancer research and a deep commitment to women's health.

Dr. Levine has been very active within the NIH-sponsored Cancer Genome Atlas project (TCGA). He serves as co-chair of the ovarian, endometrial, and uterine carcinosarcoma disease working groups. He is a member of the Scientific Advisory Committee of the Ovarian Cancer Research Fund, the Clarity Foundation, and the Honorable Tina Brozman Foundation. He has authored or co-authored more than 150 peer-reviewed articles and two textbooks. Dr. Levine has received funding from the National Cancer Institute, the Department of Defense, Stand Up 2 Cancer, and the Gynecologic Oncology Group. He has been awarded the American Congress of Obstetricians and Gynecologists Mentor Award, served as co-chair of the American Association for Cancer Research Special Conferences on Ovarian Cancer, received the 2013 Foundation for Women's Cancer Excellence in Ovarian Cancer Research Prize, and was recently named the Assistant Dean of the Department of Defense Ovarian Cancer Academy.

Christian Marth, MD, PhD

Director of the Department of Obstetrics & Gynecology Innsbruck
Austria



Christian Marth received his medical degree from the Leopold Franzens University of Innsbruck, Faculty of Medicine, in 1985, performed his residency in gynecology & obstetrics from 1985-1991, registered as a fellow in obstetrics & gynecology in 1991, and completed his habilitation and was awarded *venia legendi* in gynecology and obstetrics with the thesis "Biological modulators in ovarian cancer" from the University Innsbruck in 1991.

From 1996 – 1998 Christian Marth was senior physician at Det Norske Radiumhospital in Oslo (Norway). Since October 1998 he is the director of the Department of Obstetrics and Gynecology at the University Hospital Innsbruck.

Christian Marth is a member of many medical societies, including the European Society of Gynecologic Oncology (ESGO), the International Society of Gynecologic Cancer (IGCS), the American Society of Clinical Oncology (ASCO), the Austrian Society of Gynecology and Obstetrics (OEGGG). He is an executive board member of the Gynecologic Cancer Intergroup (GCIG). Actually he is the president of the ENGOT and of the Austrian Association for Gynecologic Oncology (AGO), vice president of the ABCSG (Austrian Breast and Colorectal Cancer Study Group).

Christian Marth has been the author or co-author of more than 370 scientific articles, reviews, and book chapters. He received 13 national and international awards.

Carol Aghajanian, MD
Gynecologic Medical Oncology Service
Memorial Sloan Kettering Cancer Center
USA



Carol Aghajanian, MD, a medical oncologist and authority on gynecologic cancers, is the Chief of the Gynecologic Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Cornell Medical College. She serves as Chair of the Developmental Therapeutics Committee of NRG Oncology, represents the NCTN groups on the Investigational Drug Steering Committee (IDSC) and serves on the Gynecologic Cancer Steering Committee (GCSC) of the National Cancer Institute. She is the Principal Investigator for the MSK, National Clinical Trials Network (NCTN), Lead Academic Participating Site (LAPS) grant. She is an active member of the International Society for the Study of Trophoblastic diseases and directs the gestational trophoblastic disease program at MSKCC. Her research focuses on developmental therapeutics as applies to gynecologic cancers. She has earned several rewards in recognition of her work including the MSKCC Louise and Allston Boyer Award for Distinguished Achievement in Biomedical Research (2003), the Visionary Medical Research Honoree by the Ovarian Cancer National Alliance (2012) and the Michael C. Christian Oncology Development Award (2014).

Gunnar B. Kristensen, MD, PhD
Department of Gynecologic Oncology
The Norwegian Radium Hospital
Oslo University Hospital
Norway



Born 1946. MD in 1972. Basic training and training as gynecologist in Denmark. Since 1975 interested in cervical preneoplasia. During the years 1982-1989 this interest was extended to the surgical treatment of gynecologic oncology. In 1989 I decided to work full time in gynecologic oncology and decided to move to the Norwegian Radium Hospital (DNR). In 1993, I was appointed as assistant chief of the department for gynecologic oncology. In 1995 I was appointed as responsible for the cervical cancer treatment program. Kolbein Sundfør was in charge of radiotherapy for cervical cancer and was an important coworker in building the cervical cancer team. Heidi Lyng was working in the section for radiation biology in the research department and we asked her to be head of the molecular biology team of the cervical cancer treatment program. Taran Hellebust have been another important coworker as radiation physicist and has made a great contribution towards the present state of modern 3D doseplanning and modern brachytherapy. In recent years our radiation oncologists also have made great contribution in this field. My research interest started with cervical preneoplasia and after the move to DNR this interest was widened to cervical cancer. I have been an assistant to many PhD theses. I defended my own thesis in 1999 on prognostic factors in early cervical cancer. In 2005 I was evaluated as competent for a professorship. In mid-1990'th I started to work on clinical studies. In 1998 I was elected as chairman of the Nordic Society for Gynecologic Oncology (NSGO). In 2006 NSGO clinical Trials Unit was build and I became the first director, serving until 2013. I have been author-coauthor of 240 peer reviewed articles and 20 book chapters.

Xavier Matias-Guiu, MD, PhD
Department of Pathology
Hospital Universitari Bellvitge
Hospital Universitari Arnau de Vilanova
Spain



Xavier Matias-Guiu (XM) obtained his PhD in 1987 in Barcelona. In 1991-92, XM was Research Fellow in Pathology at the New England Medical Centre/Tufts University in Boston, with Professors H Wolfe and R DeLellis, and the Massachusetts General Hospital with Professor Scully. From 1986 to 2002, XM worked with Professor Jaime Prat in Hospital Sant Pau, Barcelona. Currently, he combines the position of Chairman of Pathology at Hospital Universitari Bellvitge in Barcelona, Hospital Universitari Arnau de Vilanova in Lleida, and the direction of a research group as Professor of Pathology at University of Lleida, with especial focus in integrating molecular features of gynecological cancers in the appropriate microscopic context. The main areas of interest during the last 20 years have been:

- Molecular alterations in important signaling pathways in endometrial carcinoma, (microsatellite instability, as well as alterations in PTEN, PI3KCA, CTNNB1, k-RAS, Sprouty 2, FGFR2, RASSF1A), also using high throughput techniques (metabolomics, kinome assays, epigenetics, targeted and exome sequencing) in different histological types of endometrial carcinomas.
- Molecular alterations involved in myometrial invasion and metastasis in endometrial carcinoma, by assessing the differential proteomic profile, the role of Epithelial to Mesenchymal transition (EMT), the identification of Annexin 2 as a metastasis-gene, and characterization of circulating tumor cells.
- Resistance to apoptosis in endometrial carcinoma, by providing with important data, such as the role of Flip, under the control of CK2, BRAK and KSR1.
- Development of 3-D cultures from murine endometrial cells and evaluation of the role of PTEN deficiency in glandular architectural growth.
- Generation of animal models with temporal control of PTEN deletion for studying endometrial carcinogenesis.
- Resistance to hypoxia and radiation therapy, by assessing the role of NKk β and also the differential expression of proteins involved in apoptosis-resistance and adaptation to hypoxia in primary endometrial carcinomas, and postradiation recurrences.
- Targeted therapies, by assessing the effects of different anticancer agents in endometrial carcinoma in cell lines and animal models.
- Generation of orthoxenograft models for endometrial carcinoma in more than 100 patients.
- Translation into medical practice with optimization of diagnostic and prognostic tests, and participation in guidelines in medical management of patients with endometrial

Ben Davidson, MD, PhD
Department of Pathology
The Norwegian Radium Hospital
Oslo University Hospital
Norway



Education

2003-2004: Post-doctoral fellow at NCI/NIH, Bethesda MD
1998-2001: Ph.D. program, Norwegian Radium Hospital; Thesis defended 23/8/01
1986-1992: Medical studies in Sackler School of Medicine, Tel-Aviv University

Brief Chronology of employment

2002-present: Staff pathologist, Department of Pathology, Norwegian Radium Hospital, Oslo, Norway; Sub-specialist in cytopathology and gynecologic pathology
1998-2001: Resident (combined with PhD program), Department of Pathology, Norwegian Radium Hospital, Oslo, Norway
1994-1998: Resident, Department of Pathology, Sheba Medical Center, Tel Hashomer, Israel

Membership in professional and scientific societies

1. The American Association for Cancer Research
2. The International Academy of Pathology (Norwegian division)
3. The European Society of Pathology
4. The International Society of Gynecological Pathology
5. Nordic Society of Gynecologic Oncology

Scientific appointments

2012-: Editorial board member in Gynecologic Oncology
2011-: Editorial board member in Human Pathology
2010-: Editorial board member in Virchows Archiv
2011-2016: Associate Editor, Frontiers in Women's Cancer
2010: Associate Editor, Journal of Oncology, Special issue titled Molecular Genetic Markers in Female Reproductive Cancers
2006-2013: Member of the grant application committee, Norwegian Cancer Society
2005-2012: Section Editor in Diagnostic Cytopathology

Invited speaker and Reviewer

- Reviewed a large number of manuscripts for leading international peer-reviewed journals, including Nature Reviews Cancer, Lancet Oncology, Cancer Research, Clinical Cancer Research, Molecular Cancer Research, Annals of Oncology, The American Journal of Pathology, Oncogene and Cancer.
- Invited speaker in 35 sessions in international conferences in 2004-2016

Publications (excluding abstracts) in peer-reviewed journals: 295 per October 2016

William Cliby, MD
Virgil S. Counsellor Professor of Surgery
Professor, Obstetrics and Gynecology
Mayo Clinic
USA



Dr. Cliby is a gynecologic oncologist at Mayo Clinic in Rochester Minnesota and former chair of the division of Gynecologic Surgery. His clinical expertise is focused on the surgical management of gynecologic cancers, particularly ovarian cancer, and quality improvement in gynecologic oncology. He has done considerable research on the application and techniques of cytoreductive surgery for ovarian cancer and their impact on outcomes. His work has been important in the identification of risk factors for poor outcomes and strategies to reduce these risks, as well as characterizing national standards in management of ovarian cancer. In addition, Dr. Cliby is the fellowship director for gynecologic oncology and has been recognized multiple times as Teacher of the Year at Mayo. He maintains an NIH funded research lab with active funding currently directed at understanding and targeting the stroma in ovarian cancer as a potential therapeutic strategy. He is a member of the Executive Committee of the SPORE grant in Ovarian cancer at Mayo Clinic Cancer Center.

Ane Gerda Zahl Eriksson, MD
Department of Gynecologic Oncology
The Norwegian Radium Hospital
Oslo University Hospital
Norway



Dr. Eriksson received her Medical Degree from the Medical University of Warsaw in Poland and completed her residency training at Oslo University Hospital in Norway. She completed her fellowship in Gynecologic Oncology at Memorial Sloan Kettering Cancer Centre in 2015, and has since returned to the department of Gynecologic Oncology at the Norwegian Radium Hospital where she provides surgical and medical treatment for women with gynecologic malignancies. Her principal area of clinical practice is advanced minimal invasive surgery for gynecologic cancer and radical procedures for cytoreduction in ovarian cancer. She holds a special interest in image-guided surgery in endometrial, cervical and vulvar cancer, and also in the treatment of recurrent ovarian cancer.

Dr. Eriksson has a strong interest in clinical research, with an emphasis on image-guided surgery, and takes part in ongoing trials at the Norwegian Radium Hospital. She is an active member of several national and international societies.

Olesya Solheim, MD, PhD
Department of Gynecologic Oncology
The Norwegian Radium Hospital
Oslo University Hospital
Norway



Olesya Solheim has her medical education from the State Medical Academy of Arkhangelsk, Russia, 1999. After receiving her degree as medical doctor she underwent 4 years of specialization within obstetrics and gynecology from the same institution.

Dr Solheim moved to Norway in 2003 and received authorization of her medical education from Russia as professionally equivalent to the degree Candidate of Medicine of the University of Oslo (Candidata Medicinae - Cand. Med.). Having settled in Oslo she has been working at different departments of Oslo University hospital.

In the period 2006-2007, she was trained in internal medicine at Lillehammer hospital, and was in 2007 authorized as medical doctor by the Norwegian governmental office for authorization of health personnel. Since 2008 she has been working at the Oslo University Hospital, Dep. of Gynaecological Oncology, the Norwegian Radium Hospital.

August 19, 2015 Olesya Solheim defended the thesis:

“Malignant Ovarian Germ Cell Tumors: Survival and Long Term Adverse Effects”

for the degree of PhD. This project was the first national study of Germ Cell ovarian tumors and was conducted in cooperation between the Departments of gynecological oncology in Oslo, Trondheim, Bergen, Tromsø, and the National Resource Center for Studies after Treatment for Cancer OUS, the Norwegian Radium Hospital. Olesya finished her specialization in obstetrics and gynecology and obtained Norwegian specialist certificate the same year.

From September 2015 Olesya Solheim has been responsible for treatment of Rare Ovarian Tumors and Trophoblastic Diseases at Dep. of Oncological Gynaecology, Radiumhospital, Norway. She has been a participant in European Organization for Treatment of Trophoblastic Diseases collaboration and representative for our clinic in the EURACAN : European network for Rare adult solid Cancer.

Bilal M.Sert , MD
Department of Gynecologic Oncology
Oslo University Hospital
The Norwegian Radium Hospital
Norway



Born in Trabzon, Turkiye in 1956.
1973 Ataturk High School, Ankara, Turkiye.
1979 Bursa Uludag/ Istanbul University, Medical Faculty (Graduated by high honour).
1985-1989 Training in Obstetrics and Gynecology, SSK Ankara Maternity & Womens Hospital. PhD. Ankara, Turkiye.
1988 Laser Training, Queen Elizabeth Hospital, Newcastle & University of Sheffield, England.
1989 Gynecologic Oncology Research Fellow, Trondheim University & The Norwegian Radium Hospital.
1989 Royal College of Obstetricians & Gynecologists, educational course on Colposcopy, London.
1990 CUSA Training Johns Hopkins Hospital, Division of Gyn.-Oncology. Baltimore, USA.
1992 Postdoctoral Research Fellowship, Johns Hopkins Hospital, Division of Gynecologic Oncology. Baltimore, Maryland, USA.
1992 Associate Professor, Dept. of Obs. & Gyn. at Hacettepe University, School of Medicine. Ankara, Turkiye.
1995 Laparoscopic Animal Research Study, Tucson, Arizona, USA
1999 Norwegian Medical Authorization.
2000 Workshop about Laparoscopic & vaginal surgery in gynecologic oncology. Lyons and Lille, France, Daniel Dargent & Denis Querleu.
2002 European Board of College of Obstetrics and Gynecology
2004 MasterClass of Gynecologic Oncologic Surgery. Ecole Europeenne de Chirurgie.(EEC) Denis Querleu.

He is a full member of SGO, AAGL, UICC, IGCS, ESGO and founder member of SERGS. He was also served as ESGO council member in two terms between 2003- 2005 and between 2005-2007. In addition SERGS council member in two terms between 2009-2011 and 2011-2013. He is still SIG member at AAGL in both Robotics and Oncology.


He has authored or co-authored more than 100 publications and is co-author 6 book chapters

He has established the minimally invasive surgical & robotic section at the Norwegian Radium Hospital and have reported first robot assisted radical hysterectomy in the world literature in 2006. Multi-institutional robot-assisted radical hysterectomy long-term follow-up Data was published in April 2016 in European Journal surgical Oncology.

He has been working in the Norwegian Radium Hospital since 1998 as a senior consultant.

[illegible]

[illegible]



RADIUM
HOSPITAL
FOUNDATION

